Navigation Links
Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
Date:5/8/2008

ous is a very important and promising alternative to drug-eluting stents," said de Winter. "EuroPCR is the ideal venue at which we can share our findings and demonstrate the impact that the Genous technology is having on the interventional cardiology community."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Editor's Note: OrbusNeich will display the Genous Bio-engineered R stent at Booth No. F06 at EuroPCR 2008.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...y Shows Positive Results with X-ray ...Newswire/ -- Roche today announced one-year,result... ACTEMRA(TM),(tocilizumab) can significantly inhib...atients with rheumatoid arthritis (RA), a critical...study also demonstrated that ACTEMRA,reduces disea...
(Date:5/8/2008)...rovement in ADHD symptoms in adults, WASHINGTON, ...P,Nasdaq: SHPGY), the global specialty biopharmac...phase III pivotal study in which VYVANSE,demonstra...Hyperactivity,Disorder (ADHD) symptoms in adults a...s with ADHD often find it challenging to focus and...
(Date:5/8/2008)...e-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq...ator-sponsored,Phase I/II clinical trial of its le...combination with cytarabine in elderly patients wi... (AML) and high-risk,myelodysplastic syndromes (MD...on of Ellen K. Ritchie, M.D. at The Weill-Cornell ...
(Date:5/8/2008)...tion for Clinicians Concerned About ..., Fla., May 8 /- Alpharma I...maceutical company, announced today that two,studi...Society annual,meeting demonstrate the efficacy, t...f Alpharma Pharmaceuticals, FLECTOR(R) Patch (dicl...
Breaking Medicine Technology:New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Chindex International Inc Announces Transfer to NASDAQ Global Market 8764 1Chindex International Inc Announces Transfer to NASDAQ Global Market 8764 2Chindex International Inc Announces Transfer to NASDAQ Global Market 8764 3Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 1Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 2Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 3VA Hospital Draws Curtain on Innovation That Could Help Reduce Spiraling Cost of Hospital Maintenance Nationwide 8760 1VA Hospital Draws Curtain on Innovation That Could Help Reduce Spiraling Cost of Hospital Maintenance Nationwide 8760 2Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 1Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 2Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 3
...Newswire-FirstCall/ -- Sosei Group,Corporation , a...ccessful completion of a study of its fentanyl sub...e treatment of cancer,breakthrough pain. , This wa...bel,single dose, cross-over, randomised study of ... citrate lozenge) and versus fentanyl,citrate inje...
...007 /PRNewswire-FirstCall/ -- Auxilium,Pharmaceuti...ovements in symptoms of decreased libido, energy l...onadal men after switching,brands of testosterone ... increased significantly in patients who switched ...owing suboptimal,response to Solvay S.A.,s Androge...
Other Medicine Technology:Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 2Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA 3Auxilium Announces New Data That Show Total Testosterone Blood,Levels Increase Significantly Following Switch from AndroGel(R) to,Testim(R) 2Auxilium Announces New Data That Show Total Testosterone Blood,Levels Increase Significantly Following Switch from AndroGel(R) to,Testim(R) 3Auxilium Announces New Data That Show Total Testosterone Blood,Levels Increase Significantly Following Switch from AndroGel(R) to,Testim(R) 4Auxilium Announces New Data That Show Total Testosterone Blood,Levels Increase Significantly Following Switch from AndroGel(R) to,Testim(R) 5
(Date:5/12/2008)...ces of Pay-for-Performance Programs , At a time ...g, this study finds that while such programs may s...ng physician income, they also change the nature o...rses work together. In-depth interviews with 41 fa...ingdom three years after implementation of a new p...
(Date:5/11/2008)...y 11 /PRNewswire/ -- The Myanmar Relief Fund,( htt...private American and,Myanmar citizens that have th...ms bypassing bureaucratic barriers. Teams of docto...ies are being distributed., The Myanmar Relief Fu...citizens with headquarters in California and Yango...
(Date:5/11/2008)...Biotechnology and Biological Sciences Research Cou...o investigate important aspects of human ageing. ...niversity, Dr Lynne Cox and Dr Robert Saunders hav...s can now be used to study the effects ageing has ...l Aging Cell, the researchers demonstrate the valu...
(Date:5/11/2008)... 20). Senior White House Correspondent Richard,Wol... at the presidential,candidate,s leadership and ma...or the coming mud war with John McCain and the Rep...ll be about the big issues because there,are stark...e economy.,They,re also ready for attacks from ano...
Breaking Medicine News(10 mins):Health News:May/June 2008 Annals of Family Medicine tip sheet 2Health News:May/June 2008 Annals of Family Medicine tip sheet 3Health News:May/June 2008 Annals of Family Medicine tip sheet 4Health News:May/June 2008 Annals of Family Medicine tip sheet 5Health News:May/June 2008 Annals of Family Medicine tip sheet 6Health News:Human aging gene found in flies 2Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 2Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 3Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 4Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 5
...t Harvard Nurses' Health study, women who drink fo...loping gallstones than those who do not drink coff...esults. Women are twice as likely to be affected w...en who are overweight or have experienced rapid we...
...urvey of more than 149,000 Americans including 23,...ity showed that 25% of adults with disabilities, c... a risk of obesity.// Obesity was defined as havin...he study also highlighted that adults with lower l...
...study researchers have observed that there is evid...l, is the best way forward in peripheral arterial ...r over will be affected by peripheral arterial dis...ue, in the leg arteries leads to pain, aching, and...
...rs it is observed that a drug already being used t...ective male contraceptive. Researchers hypothesize...en approved in Europe to treat Gaucher's disease, ...ffects the metabolism of sugar-fat compounds essen...
Other Medicine News:
The Labcyte Echo 550 compound reformatter performs direct microplate-to-microplate transfers of droplets down to 5 nL using a new "touchless" transfer technology based on focused acoustic energy. Mon
Wellpro 384, compatible with hood installations. An automated liquid handling system for 384-well plates, that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also
Precise, nanoliter-volume liquid handling capability allows you to accurately dispense volumes as small as 5 nanoliters. Precision robotics and flexible software ensure accurate, repeatable X/Y motio
... series of robotic workstations is designed for la...e ideal automation platform for routine sample pre...procedures, improving throughput, process consiste...rep software allows you to control the robotic and...
Medicine Products: